PROGNOSTIC HETEROGENEITY AMONG HIGH RISK MULTIPLE MYELOMA PATIENTS (T(4-14) AND DEL17P) ACCORDING TO ADDITIONAL CYTOGENETIC ABNORMALITIES, THE IFM EXPERIENCE

被引：0

作者：

Benjamin, H. ^{[1
]}

Florence, M. ^{[2
]}

Alice, C. ^{[3
,4
]}

Valerie, L. C. ^{[1
]}

Marie-Lorraine, C. ^{[5
]}

Cyrille, H. ^{[6
]}

Xavier, L. ^{[7
]}

Gerald, M. ^{[8
]}

Lionel, K. ^{[9
]}

Murielle, R. ^{[1
]}

Philippe, R. ^{[10
]}

Catherine, S. ^{[9
]}

Francois, L. ^{[11
]}

Sabine, B. ^{[12
]}

Marie, S. Anne ^{[13
]}

Marc, W. ^{[14
]}

Frederique, O. P. ^{[15
]}

Sylvie, C. ^{[16
]}

Gerard, L. ^{[17
]}

Brrigitte, P. ^{[18
]}

Karim, B. ^{[19
]}

Jean, F. ^{[20
]}

Laurent, V. ^{[21
]}

Laurent, G. ^{[22
]}

Bruno, R. ^{[23
]}

Mamoun, D. ^{[24
]}

Margaret, M. ^{[25
]}

Denis, C. ^{[26
]}

Mohamad, M. ^{[22
]}

Thierry, F. ^{[7
]}

Philippe, M. ^{[27
]}

Michel, A. ^{[28
]}

Jill, C. ^{[29
,30
]}

Stephane, M. ^{[27
]}

Herve, A. L. ^{[31
,32
]}

机构：

[1] Hop Purpan, Toulouse, France

[2] UMR S 892, Nantes, France

[3] Hop Rangueil, Unite Genom Myelome, Toulouse, France

[4] Hop Rangueil, INSERM, U1037, CRCT, Toulouse, France

[5] Hop Dijon, Dijon, France

[6] Ctr Univ Nancy Brabois, Nancy, France

[7] CHRU Lille, F-59037 Lille, France

[8] Grp Hosp Haut Leveque, Bordeaux, France

[9] CHU Lyon, Lyon, France

[10] CH Perigueux, Perigueux, France

[11] CH DAX, Dax, France

[12] Hop Avicenne, Paris, France

[13] Inst J Paoli I Calmettes, F-13009 Marseille, France

[14] CH DUNKERQUE, Dunkerque, France

[15] CH Annecy, Annecy, France

[16] CH AIX, Aix En Provence, France

[17] CH AVIGNON, Avignon, France

[18] CH Grenoble, Grenoble, France

[19] AP HP, Paris, France

[20] CH Besancon, Besancon, France

[21] CH Chalon, Chalon Sur Saone, France

[22] CH St Antoine, Paris, France

[23] CH Amiens, Amiens, France

[24] CH Angers, Angers, France

[25] CH Caen, Caen, France

[26] CH DIJON, Dijon, France

[27] CHU Nantes, F-44035 Nantes 01, France

[28] Inst Claudius Regaud, Toulouse, France

[29] CHU Purpan, Unite Genom Myelome, Toulouse, France

[30] CHU Purpan, INSERM, U1037, CRCT, Toulouse, France

[31] CHU Toulouse, Unite Genom Myelome, Toulouse, France

[32] CHU Toulouse, INSERM, U1037, CRCT, Toulouse, France

来源：

HAEMATOLOGICA | 2014年 / 99卷

关键词：

D O I：

暂无

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

S1287

引用

页码：495 / 495

页数：1

共 47 条

[41] Clinical implications of t(11;14)(q13;q32), t(4;14)(p16.3;q32), and-17p13 in myeloma patients treated with high-dose therapy
Gertz, MA
Lacy, MQ
Dispenzieri, A
Greipp, PR
Litzow, MR
Henderson, KJ
Van Wier, SA
Ahmann, GJ
Fonseca, R
BLOOD, 2005, 106 (08) : 2837 - 2840
[42] Clinical implications of 13q14 and 17p13 deletion, t(4;14) and 1q21 amplification in patients with relapsed multiple myeloma treated by Thalidomide or Bortezomib (Velcade)
Kuglik, P.
Zaoralova, R.
Filkova, H.
Greslikova, H.
Nemec, P.
Oltova, A.
Pour, L.
Adam, Z.
Krejci, M.
Hajek, R.
CHROMOSOME RESEARCH, 2007, 15 : 185 - 186
[43] Clinical implications of t(11;14)(q13;q32), t(4;14)(p16.3;q32) and - 17p13 (p53) deletions in myeloma patients treated with high dose therapy
Gertz, MA
Lacy, MQ
Dispenzieri, A
Greipp, PR
Litzow, MR
Henderson, KJ
Van Wier, SA
Ahmann, GJ
Fonseca, R
BLOOD, 2004, 104 (11) : 99A - 99A
[44] Bortezomib-Based Induction and Maintenance Overcomes the Negative Prognostic Impact of Renal Impairment and del17p in Transplant-Eligible Myeloma Patients: Long Term Results from the Phase III HOVON-65/GMMG-HD4 Study after Median 137 Months Follow up
Scheid, Christof
Lokhorst, Henk
Blau, Igor W.
Van der Holt, Bronno
Bertsch, Uta
Zweegman, Sonja
Weisel, Katja
Vellenga, Edo
Kersten, Marie Jose
Croockewit, Sandra
Mai, Elias K.
Raymakers, Reinier
Hose, Dirk
Jauch, Anna
Hillengass, Jens
Stevens-Kroef, Marian
Raab, Marc S.
Neben, Kai
Stilgenbauer, Stephan
Broyl, Annemiek
Lindemann, Hans-Walter
Bos, Gerard
Brossart, Peter
Kooij, Marinus van Marwijk
Ypma, Paula F.
Duehrsen, Ulrich
Schaafsma, Ron
Hielscher, Thomas
Salwender, Hans
Goldschmidt, Hartmut
Sonneveld, Pieter
BLOOD, 2019, 134
[45] Interphase FISH-defined amplification of chromosome 1q21 (AMP1q21) identify high-risk subsets among patients with multiple myeloma (MM) lacking metaphase cytogenetic abnormalities (CA).
Shaughnessy, J
Hanamura, I
Burington, B
Sawyer, J
Crowley, J
Barlogie, B
BLOOD, 2005, 106 (11) : 185A - 185A
[46] FISH Abnormalities (including R-ISS defining and IgH mutations) Are Similar across Race and Ethnicity Among Patients with Multiple Myeloma (except higher rates of t(4:14) in Minorities and 1q Amplifications in Asian/Indians)
Biran, Noa
Johnson, Camille
Norden, Andrew D.
Kumar, Roger
Vesole, David H.
Berk, Seth H.
Fitzgerald, Denis B.
Siegel, David S.
Goldberg, Stuart L.
BLOOD, 2018, 132
[47] Combining Information Regarding Chromosomal Aberrations t(4;14), Del(17p13) and the Copy Number of 1q21 with the International Staging System Classification Allows Stratification of Myeloma Patients Undergoing Autologous Stem Cell Transplantation: Results From the HOVON-65/GMMG HD4 Trial
Neben, Kai
Lokhorst, Henk M.
Jauch, Anna
Bertsch, Uta
Hielscher, Thomas
Heiss, Christiane
van der Holt, Bronno
Schmitt, Stefan
El Jarari, Laila
Salwender, Hans J.
Blau, Igor W.
Pfreundschuh, Michael
Weisel, Katja
Duehrsen, Ulrich
Lindemann, Walter
Teschendorf, Christian
Martin, Hans
Scheid, Christof
Haenel, Mathias
Derigs, Hans Guenter
Graeven, Ullrich
Schmidt-Wolf, Ingo G. H.
Peter, Norma
Wattad, Mohammed
Luntz, Steffen P.
Broyl, Annemiek
Schubert, Joerg
Hoffmann, Martin
Goerner, Martin
Tischler, Jochen
Kaufmann, Martin
Raab, Marc S.
Ho, Anthony D.
van de Velde, Helgi
Hose, Dirk
Sonneveld, Pieter
Goldschmidt, Hartmut
BLOOD, 2011, 118 (21) : 156 - 156

← 1 2 3 4 5 →